 phase II studi high-dos high-dos leucovorin low-dos phosphonacetyl-l-aspart acid patient advanc malign twenty-eight patient refractori advanc malign infus LV N- phosphonacetyl -l-aspart acid pala twenty-seven patient evalu toxic antitumor activ pala intraven bolu minut dose hour start leucovorin infus dose LV fix dose period regimen diarrhea stomat nausea dose-limit toxic other hand-foot syndrom hair loss scalp eyelash overal weak rhiniti chemic conjunct maximum dose combin schedul seven patient abl chemotherapi weekli basi interrupt patient dose reduct receiv dose patient patient partial respons complet respons patient pancreat carcinoma overal respons rate patient patient untreat patient pancreat cancer treatment complet respons patient non-smal cell lung cancer partial respons patient breast cancer ten patient colorect cancer treatment partial respons